Development of a Targeted Treatment for Cancer

摘要: This is a review of the discovery and development C225/Cetuximab, novel monoclonal antibody (mAb) treatment for cancer. Cetuximab was first anticancer agent that successfully targeted receptor growth factor protein tyrosine kinase. Blocking signaling activity epidermal (EGF) represented new approach to cancer therapy. Preclinical studies with human xenografts suggested C225 worked best in combination chemotherapy or radiation. Many possible mechanisms action have been uncovered, including inhibition each six characteristics cell described by Hanahan Weinberg (1). The research on over period two decades has involved dozens academic collaborations, numerous grants from National Cancer Institute, work four pharmaceutical/biotech companies. There setback Food Drug Administration (FDA) process, but approval clinical use advanced refractory colorectal obtained 2004. Much additional needed (and ongoing) discover markers predict responsiveness determine how whom this therapy most effectively.